[Effect of insulin-binding antibodies on the kinetics of intra- venous insulin in diabetes mellitus].
The kinetics of 131I-labeled intravenous insulin was examined in 13 patients with diabetes mellitus and in 2 nondiabetics, and the kinetics of unlabeled intravenous insulin ('insulrap') was followed up in 7 patients with insulin-dependent diabetes. Antibodies to exogenous insulin were titered in examinees' blood sera. The kinetic curves of labeled and unlabeled insulin were processed with the use of a two-compartmental model, thus obtaining compatible kinetics parameters. This permits the use of routine insulin dosage forms in pharmacokinetic studies, followed by the blood serum insulin radioimmunoassay. Antibodies to exogenous insulin increase the level of insulin dissemination, slow down its elimination from the blood (mostly in the beta-phase) and the total insulin clearance, with the antibody titer rise being parallelled by an acceleration+ of insulin dissemination and by deceleration of its elimination from the blood; besides, the fraction of antibodies, by fixing which insulin is slowly metabolized, increases.
Dreva'l
A V
AV
Gite'l
E P
EP
Dreva'l
T P
TP
D001666:Binding Sites, Antibody / Q000502:physiology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007330:Insulin Antibodies / Q000502:physiology*; D007333:Insulin Resistance / Q000502:physiology*; D008657:Metabolic Clearance Rate / Q000502:physiology
D007328:Insulin; D007330:Insulin Antibodies
Vliianie insulinsviazyvaiushchikh antitel na kinetiku vnutrovenno vvedennogo insulina pri sakharnom diabete.